Physician profile
Solly S Chedid
NPI 1972586188
$1,717,784.83
in general payments reported to CMS, 2019-2025
81 companies · $302K in 2025
The $302K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158K · 2020: $123K · 2021: $198K · 2022: $272K · 2023: $354K · 2024: $310K · 2025: $302K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $676K · Consulting Fee: $157K · Travel and Lodging: $109K · Food and Beverage: $21K · Honoraria: $2,540 · Education: $75.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $676,304.98 |
| Consulting Fee | $157,141.90 |
| Travel and Lodging | $109,322.78 |
| Food and Beverage | $21,027.43 |
| Honoraria | $2,540.00 |
| Education | $75.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $436,260.10 | 2019-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $185,524.58 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $183,988.70 | 2019-2025 | Reblozyl, Pomalyst, Onureg |
| Ipsen Biopharmaceuticals, INC | $134,662.54 | 2020-2025 | Tazverik, Onivyde, Somatuline Depot |
| Daiichi Sankyo INC. | $130,010.71 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $103,731.31 | 2019-2025 | Reblozyl, Pomalyst |
| Genzyme Corporation | $60,702.33 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $52,068.36 | 2019-2025 | Calquence, Imfinzi, Lumoxiti |
| Seagen INC. | $51,686.88 | 2019-2023 | Padcev, Tukysa |
| Pfizer INC. | $51,231.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $47,325.15 | 2020-2025 | Ojjaara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36,151.49 | 2019-2025 | Gilotrif |
| Pharmaessentia USA Corporation | $29,161.29 | 2024-2025 | Besremi |
| Astellas Pharma US INC | $28,567.45 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Incyte Corporation | $27,917.23 | 2020-2025 | Zynyz, Jakafi, Monjuvi |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $26,790.36 | 2025 | Rytelo |
| Amgen INC. | $24,288.22 | 2019-2023 | Lumakras, Kyprolis, Xgeva |
| Epizyme, INC. | $22,995.91 | 2020-2022 | |
| Janssen Biotech, INC. | $16,757.26 | 2019-2025 | Rybrevant, Carvykti, Akeega |
| Taiho Oncology, INC. | $15,050.19 | 2019-2024 | |
| Exelixis INC. | $9,258.12 | 2019-2025 | Cabometyx |
| Teva Pharmaceuticals USA, INC. | $7,828.66 | 2019 | |
| Puma Biotechnology, INC. | $5,431.86 | 2019-2025 | |
| Genentech USA, INC. | $5,315.30 | 2019-2025 | Columvi, Polivy, Lunsumio |
| Agios Pharmaceuticals, INC. | $5,005.01 | 2019-2023 | Pyrukynd |
| Janssen Scientific Affairs, LLC | $3,611.48 | 2019-2025 | Tecvayli |
| Pharmacosmos Therapeutics INC. | $3,117.78 | 2023-2025 | Monoferric |
| Astellas Pharma Global Development | $2,400.00 | 2025 | Vyloy |
| Beigene USA, INC. | $2,006.53 | 2020-2025 | Brukinsa |
| Gilead Sciences, INC. | $1,610.00 | 2022 | |
| Blueprint Medicines Corporation | $1,512.00 | 2021 | |
| Morphosys, US INC. | $1,293.11 | 2021-2023 | Monjuvi |
| Novartis Pharmaceuticals Corporation | $602.16 | 2019-2025 | |
| Eisai INC. | $363.64 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $315.11 | 2019-2025 | |
| Cardinal Health 110 LLC | $300.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.61 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Lilly USA, LLC | $250.62 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $244.52 | 2019-2025 | Venclexta |
| Alexion Pharmaceuticals, INC. | $218.08 | 2022-2024 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $161.60 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $150.72 | 2019-2021 | |
| Foundation Medicine, INC. | $131.54 | 2019-2023 | |
| Genmab U.S., INC. | $130.47 | 2023-2025 | Epkinly, Tivdak |
| Adaptive Biotechnologies Corporation | $128.28 | 2023-2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $119.63 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Karyopharm Therapeutics INC. | $80.60 | 2022-2024 | Xpovio |
| Aveo Pharmaceuticals, INC. | $60.04 | 2025 | |
| Azurity Pharmaceuticals, INC. | $51.95 | 2025 | Danziten |
| Emd Serono, INC. | $50.47 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $50.13 | 2025 | Alymsys |
| Sobi, INC | $47.12 | 2022-2023 | |
| Tersera Therapeutics LLC | $46.41 | 2019-2023 | Zoladex |
| Alnylam Pharmaceuticals INC. | $41.90 | 2022-2024 | Givlaari |
| Dendreon Pharmaceuticals LLC | $41.38 | 2024 | Provenge |
| Tesaro, INC. | $39.65 | 2019 | |
| Jazz Pharmaceuticals INC. | $39.57 | 2019 | |
| Beone Medicines USA, INC. | $36.13 | 2025 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $34.79 | 2024 | Orserdu |
| Kite Pharma, INC. | $25.12 | 2020 | |
| Deciphera Pharmaceuticals INC. | $24.98 | 2021 | |
| G1 Therapeutics, INC. | $23.72 | 2022 | |
| Myovant Sciences INC. | $23.02 | 2021 | |
| Verastem, INC. | $22.62 | 2019 | |
| Sumitomo Pharma America, INC. | $22.51 | 2024 | Orgovyx |
| Eusa Pharma (US) LLC | $21.85 | 2020 | |
| Recordati_rare_diseases_inc. | $21.71 | 2024 | Sylvant |
| Adc Therapeutics America, INC. | $21.43 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $20.51 | 2020 | |
| Secura Bio, INC. | $20.30 | 2021 | |
| Biocompatibles, INC. | $19.33 | 2019 | |
| Global Blood Therapeutics, INC. | $18.67 | 2022 | |
| Caris Mpi, INC. | $18.52 | 2025 | Mi Cancer Seek |
| Novocure INC. | $18.26 | 2025 | Optune Lua (Novottf-200t) |
| Kyowa Kirin, INC. | $17.66 | 2020 | |
| Immunomedics, INC. | $17.38 | 2020 | |
| Mylan Institutional INC. | $16.63 | 2019 | |
| Dova Pharmaceuticals | $16.28 | 2020 | |
| Medtronic, INC. | $16.28 | 2025 | Osteocool Rf Ablation System |
| Tactile Systems Technology INC | $15.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solly Chedid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.